CRISPR & Cas Genes Market (By Product and Services; By Application: Agricultural and Biomedical; End-User: Contract Research Organizations (CROs), Academics & Government Research Institutes and Biotechnology & Pharmaceutical Companies) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2023 - 2032

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global CRISPR & Cas Genes Market, By Product & Service

7.1. CRISPR & Cas Genes Market, by Product & Service Type, 2023-2032
7.1.1. Service
7.1.1.1. Market Revenue and Forecast (2021-2032)
7.1.2. Product
7.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 8. Global CRISPR & Cas Genes Market, By Application

8.1. CRISPR & Cas Genes Market, by Application, 2023-2032
8.1.1. Agricultural
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Biomedical
8.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global CRISPR & Cas Genes Market, By End-Use

9.1. CRISPR & Cas Genes Market, by End-Use, 2023-2032
9.1.1. Contract Research Organizations (CROs)
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Academics & Government Research Institutes
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Biotechnology & Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global CRISPR & Cas Genes Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.1.2. Market Revenue and Forecast, by Application (2021-2032)
10.1.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.1.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.1.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.1.5.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.2.2. Market Revenue and Forecast, by Application (2021-2032)
10.2.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.2.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.2.5.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2032)
10.2.6.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.2.7.2. Market Revenue and Forecast, by Application (2021-2032)
10.2.7.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.3.2. Market Revenue and Forecast, by Application (2021-2032)
10.3.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.3.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.3.5.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2032)
10.3.6.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.3.7.2. Market Revenue and Forecast, by Application (2021-2032)
10.3.7.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.4.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.4.5.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2032)
10.4.6.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.4.7.2. Market Revenue and Forecast, by Application (2021-2032)
10.4.7.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.5.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2032)
10.5.4.3. Market Revenue and Forecast, by End-Use (2021-2032)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product & Service (2021-2032)
10.5.5.2. Market Revenue and Forecast, by Application (2021-2032)
10.5.5.3. Market Revenue and Forecast, by End-Use (2021-2032)

Chapter 11. Company Profiles

11.1. Caribou Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cellectis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Editas Medicine, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Addgene
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Egenesis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Horizon Discovery Group Plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Intellia Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genscrip
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Danaher Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Lonza
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Synthego
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Mammoth Biosciences
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Inscripta, Inc.
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Cibus
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. New England BioLabs
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Takara Bio, Inc.
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample